{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-098457","form_type":"8-K","ticker":null,"cik":"0001733413","company_name":"TFF Pharmaceuticals, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.399626+00:00","generated_at":"2026-05-30T00:31:39.000110+00:00","sec_items":["1.02","2.05","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"TFF Pharmaceuticals dissolves, terminates all employees, appoints new CEO to wind down","bullets":["Board approved Plan of Dissolution subject to stockholder vote; license pact with UT Austin terminated.","Substantially all employees terminated Nov 15; estimated $1.8M in severance and exit costs.","Entire board and top officers (CEO, CFO, CMO) resigned; Craig Jalbert appointed sole director/officer.","Jalbert to receive $10K/month until shareholder vote, then $50K/year for three years post-dissolution.","Company will wind down operations and dissolve, pending stockholder approval of the plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-098457","json":"https://secwatch.observer/filing/0001213900-24-098457.json","markdown":"https://secwatch.observer/filing/0001213900-24-098457.md","text":"https://secwatch.observer/filing/0001213900-24-098457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/ea0221102-8k_tffpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:31:39.000110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05487073e8","claim":"Kirk Coleman departed as Chief Financial Officer at TFF Pharmaceuticals, Inc..","evidence_excerpt":"Harlan Weisman, M.D., Kirk Coleman and Zamaneh Mikhak, Ph.D., ceased serving as President/Chief Executive Officer, Chief Financial Officer and Chief Medical Officer, respectively, to be effective as of November 14, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"15ed93621d","claim":"Zamaneh Mikhak departed as Chief Medical Officer at TFF Pharmaceuticals, Inc..","evidence_excerpt":"Harlan Weisman, M.D., Kirk Coleman and Zamaneh Mikhak, Ph.D., ceased serving as President/Chief Executive Officer, Chief Financial Officer and Chief Medical Officer, respectively, to be effective as of November 14, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"24249a7cba","claim":"Harlan Weisman departed as President/Chief Executive Officer at TFF Pharmaceuticals, Inc..","evidence_excerpt":"Harlan Weisman, M.D., Kirk Coleman and Zamaneh Mikhak, Ph.D., ceased serving as President/Chief Executive Officer, Chief Financial Officer and Chief Medical Officer, respectively, to be effective as of November 14, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"President/Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"2a67a150c5","claim":"Brandi Roberts resigned as Member of the Board at TFF Pharmaceuticals, Inc..","evidence_excerpt":"Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board"}],"fact_type":"executive_change"},{"claim_id":"35106338a6","claim":"Craig R. Jalbert was appointed as President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary at TFF Pharmaceuticals, Inc..","evidence_excerpt":"the Board appointed Craig R. Jalbert, age 63, as the Company's President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and sole member of the Board, effective November 14, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary"}],"fact_type":"executive_change"},{"claim_id":"5b7fdd06fb","claim":"Thomas King resigned as Member of the Board at TFF Pharmaceuticals, Inc..","evidence_excerpt":"Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board"}],"fact_type":"executive_change"},{"claim_id":"6507d6af78","claim":"Harlan Weisman resigned as Member of the Board at TFF Pharmaceuticals, Inc..","evidence_excerpt":"Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board"}],"fact_type":"executive_change"},{"claim_id":"75db36a2ec","claim":"Stephen Rocamboli resigned as Member of the Board at TFF Pharmaceuticals, Inc..","evidence_excerpt":"Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board"}],"fact_type":"executive_change"},{"claim_id":"925a9d9b4c","claim":"Craig R. Jalbert was appointed as Sole member of the Board at TFF Pharmaceuticals, Inc..","evidence_excerpt":"the Board appointed Craig R. Jalbert, age 63, as the Company's President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and sole member of the Board, effective November 14, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Sole member of the Board"}],"fact_type":"executive_change"},{"claim_id":"c3becd594a","claim":"Catherine Lee resigned as Member of the Board at TFF Pharmaceuticals, Inc..","evidence_excerpt":"Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board"}],"fact_type":"executive_change"},{"claim_id":"f8c366f26b","claim":"Robert J. Mills resigned as Member of the Board at TFF Pharmaceuticals, Inc..","evidence_excerpt":"Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board"}],"fact_type":"executive_change"},{"claim_id":"2dc6ebb3f3b506a6e3879f8590afa9048f5f0301","claim":"TFF Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.8 million (substantially all of its employees).","evidence_excerpt":"On November 14, 2024, in connection with the planned wind down of the Company’s operations, the Board of the Company unanimously approved a reduction-in-force (the “Reduction in Force”) of substantially all of its employees to be effective on November 15, 2024. The Company expects to incur one-time charges and cash expenditures associated with the workforce reduction of approximately $1.8 million","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.8 million"},{"label":"Headcount","value":"substantially all of its employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}